Circulating Tumour Cells (CTC) Trial

NIIM conducts the Circulating Tumour Cells (CTC) Test as part of a clinical study.

The study has been approved by an NHMRC registered ethics committee, and is registered on the Australia New Zealand Clinical Trial Registry.

The Circulating Tumour Cells (CTC) Trial is ongoing.

What is Circulating Tumour Cell (CTC) analysis?

The ISET CTC Test

  • The ISET CTC Test is a screening test not a diagnositc test
  • CTCs are Circulating Tumour Cells in the blood
  • CTCs provide a biomarker for early cancer prognosis and treatment effectiveness
  • The number of CTC or CTC count indicates the risk of malignancy or the stage of cancer
  • Isolation by Size of Epithelial Tumour (ISET)-CTC testing using filtration and analysis by microscopy using standard cytological criteria, validated in more than 80+ peer-reviewed articles over the last 20 years. Articles can be downloaded at: https://www.rarecells.com/oncology
  • As of April 2019, NIIM has conducted over 1,800 tests.
  • Some facts about ISET-CTC Test

Information for Practitioners and Participants

Participation in the CTC trial is by practitioner’s referral only.

For more information & Expressions of Interest

View ANZ Clinical trial registry

Contact the Research Assistants Nikolaj Travica or Ranjini Dorairaj.
P: 03 9912 9580
E: ntravica@niim.com.au or ranjinid@niim.com.au

Director of Research and Principal Investigator
A/Prof Dr Karin Ried
E: karinried@niim.com.au

Some FACTS about the ISET-CTC Test:

  1. FACT 1: The ISET-CTC tests can detect Circulating Tumour Cells (CTC) in all cancer types, including solid tumours and blood type cancers.
  2. FACT 2: The ISET-CTC test can detect small cell cancer cells. ISET-CTC (Isolation of Epithelial Tumour Cells by Size) testing by microfiltration can detect cancer cells of all sizes. Cancer cells usually are larger than 8 microns (the ISET filter hole size), including solid tumour cells of 11.7-23.8 microns, small-cell type cancers (e.g. small cell lung carcinoma of 7.2-10 microns) and blood type cancers (e.g. leukemia cells of 8.9-15.3 microns).​​
  3. FACT 3: The ISET-CTC can detect Circulating Tumour Cells (CTC) independent of the presence of Epithelial Cell Adhesion Molecule (EpCAM) markers.
    – Some tumour cells do not have EpCAM markers, e.g. blood type tumours.
    – Tumour cells consistently undergo change and may lose EpCAM markers over time.
  4. FACT 4: The ISET-CTC testing can distinguish between malignant Circulating Tumour Cells (CTC) and benign Circulating Epithelial Cells (CEC).

References

80+ peer-reviewed articles on ISET-CTC testing are available at: https://www.rarecells.com/oncology

Key articles:

  1. Ilie M et al. “Sentinel” Circulating Tumor Cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. Plos One 2014;9(10):e111597.
  2. Cristofanilli M et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351(8):781-91.
  3. Yan WT et al. Circulating tumour cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Scientific Reports 2017;7: 43464.
  4. Wang C et al. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Breast Cancer Res Treat 2017;161(1):83-94.
  5. Vona G et al. Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulating tumor cells. Am J Pathol 2000;156(1):57-63.
  6. Laget S et al. Technical insights into highly sensitive isolation and molecular characterization of fixed and live circulating tumor cells for early detection of tumor invasion. PloS One 2017, 12(1), p.e0169427.
  7. Ried K, Eng P, Sali A. Screening for Circulating Tumour Cells allows early detection of cancer and monitoring of treatment effectiveness: an observational study. Asian Pac J Cancer Prev 2017; 18: 2275-2285.